You are here: Industry Insights > Boehringer Ingelheim

News List

European Commission approves Jardiance to treat heart failure expresspharma
June 22, 2021
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and ...
Boehringer Ingelheim allocates one million Euros to fight COVID-19 in India expresspharma
May 19, 2021
Boehringer Ingelheim informed that it is making available one million Euros for COVID relief fund to enable sustenance and livelihoods of underserved and tribal communities, and address medical needs of patients in India, through the 2021-22 financial ...
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management expresspharma
March 26, 2021
In addition to Human Pharma, Boehringer Ingelheim India’s Animal Health business, which focuses on advanced, preventive health solutions for Pets and Poultry, aims to more than double the sales over the coming five years.
Boehringer Ingelheim reports positive business growth in 2020 pharmaceutical-technology
March 25, 2021
Boehringer Ingelheim has seen positive business momentum in 2020, according to an annual report published by the biopharmaceutical company on Wednesday.
Boehringer Ingelheim, Gubra to validate new Peptides for obesity pharmaceutical-business-review
March 05, 2021
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Psychiatry Consortium funds project investigating new schizophrenia treatments pharmatimes
January 26, 2021
The international Psychiatry Consortium has funded its first project – a partnership which will investigate a new drug target for the treatment of schizophrenia.
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy prnasia
January 19, 2021
Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies.
Boehringer Ingelheim, Enara Bio sign pact to discover novel shared antigens for cancer immunotherapies expresspharma
January 13, 2021
Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen discovery platform.
Boehringer Ingelheim announces partnership with Google pharmatimes
January 12, 2021
German pharma company Boehringer Ingelheim has signed a collaborative agreement with Google Quantum AI to research and implement quantum computing in pharma research and development.
Boehringer Ingelheim appoints Vani Manja as Country MD for India expresspharma
January 12, 2021
She was formerly the Global Head of Boehringer Ingelheim’s Go-To-Market and Business Steering organisation, based in the company’s headquarters in Germany.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page